SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 1428, 2016

REJUVEL BIO-SCIENCES, INC.

(Exact name of Company as specified in its charter)

Florida	0-53698	27-1116025
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)
	15800 Pines Blvd. Suite 3116 Pembroke Pines, Florida 33027
	(Address of principal executive offices)
	(800) 670-0448
	(Company’s Telephone Number)
	(Company’s Telephone Number) Chase Bank Building 150 SE 2nd Ave, Suite 403 Miami, Florida 33131 (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Forward-Looking~~Item ~~Statements~~3.02 – UNREGISTERED SALES OF EQUITY SECURITIES

~~This~~Effective ~~Current~~September ~~Report~~28, on2016, ~~Form 8-K (including~~ the ~~exhibit)~~Board ~~contains “forward-looking statements” within the meaning~~ of ~~the~~Directors ~~Section 27A~~ of ~~the~~Rejuvel ~~Securities Act and Section 21E of the Exchange Act. Forward~~Bio-~~looking~~Sciences, ~~statements discuss matters that are not historical facts~~Inc. ~~Because they discuss future events or conditions~~, ~~forward-looking~~a ~~statements~~Florida ~~may~~corporation ~~include~~(the ~~words such as~~ “~~anticipate,~~Company” ~~“believe~~),” ~~“estimate,”~~with ~~“intend,”~~the ~~“could,”~~approval ~~“should,”~~of ~~“would,”~~a ~~“may,”~~majority ~~“seek,”~~of ~~“plan,”~~its ~~“might,”~~shareholders ~~“will,”~~by ~~“expect,”~~written ~~“predict~~consent,” ~~“project,”~~approved ~~“forecast,” “potential,” “continue” negatives thereof or similar expressions. These forward-looking statements are found at various places throughout~~ the ~~this~~issuance ~~Current~~of ~~Report~~17,253 ~~(including~~shares ~~the exhibit) and include information concerning possible or assumed future results~~ of ~~our~~Series ~~operations;~~A ~~business~~Preferred ~~strategies;~~Stock ~~future~~at ~~cash~~a ~~flows;~~price ~~financing~~per ~~plans;~~share ~~plans and objectives~~ of ~~management; any other statements regarding future operations~~$2.898, ~~future~~to ~~cash~~our ~~needs,~~President ~~business plans~~ and ~~future financial results~~Director, ~~and~~in ~~any~~exchange ~~other~~for ~~statements~~the ~~that~~cancellation ~~are~~of ~~not~~$50,000 ~~historical~~of ~~facts~~indebtedness.

~~Any~~Effective orSeptember ~~all~~28, of2016, the ~~forward-looking~~Board ~~statements~~of ~~included~~Directors ~~in this Current Report (including the exhibit) and in any other reports or public statements made by us are not guarantees~~ of ~~future~~Rejuvel ~~performance and may turn out to be inaccurate. These forward~~Bio-~~looking statements represent our intentions~~Sciences, ~~plans~~Inc., ~~expectations,~~a ~~assumptions~~Florida ~~and~~corporation ~~beliefs~~(the ~~about future events and are subject to risks~~“Company”), ~~uncertainties~~with ~~and~~the ~~other~~approval ~~factors. Many~~ of ~~those~~a ~~factors~~majority ~~are outside~~ of ~~our~~its ~~control~~shareholders ~~and~~by ~~could~~written ~~cause~~consent, ~~actual~~approved ~~results to differ materially from~~ the ~~results~~issuance ~~expressed or implied by those forward-looking statements. In light~~ of ~~these risks~~6, ~~uncertainties and assumptions~~896,552 ~~the~~shares ~~events~~of ~~described~~Series inC ~~the~~Preferred ~~forward-looking~~Stock ~~statements might not occur or might occur to a different extent or~~ at a ~~different~~price ~~time~~per ~~than~~share weof ~~have described~~$0. ~~You are cautioned not to place undue reliance on these forward-looking statements~~0029, which speak only as of the date of this Current Report (including the exhibit). All subsequent written and oral forward-looking statements concerning other matters addressed in this Current Report (including the exhibit) and attributable to ~~us or any person acting on~~ our ~~behalf~~President ~~are~~and ~~expressly~~Director, ~~qualified~~ in ~~their~~exchange ~~entirety~~for by the ~~cautionary~~cancellation ~~statements~~of ~~contained or referred to in this Current Report (including the exhibit). Except to the extent required by law~~$20,000 ~~we undertake no obligation to update or revise any forward-looking statements, whether as a result~~ of ~~new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise~~indebtedness.

~~Item~~Effective November 1, 2016, the Board of Directors of Rejuvel Bio-Sciences, Inc.01, ~~Entry~~a ~~into~~Florida corporation (the “Company”), with the approval of a ~~Material~~majority ~~Definitive~~of ~~Agreement~~its shareholders by written consent, approved the issuance of 330,000,000 shares of Common Stock at a price per share of $0.001, to our President and Director, in exchange for the cancellation of $330,000 of indebtedness.

OnWe ~~September~~claim ~~14, 2016, the Circuit Court within Manatee County Florida issued~~ an ~~Order~~exemption ~~approving~~from aregistration ~~Settlement~~afforded ~~Agreement~~by (the “Agreement”), dated as of September 13, 2016, between Rejuvel Bio-Sciences, Inc. (the “Company”) and Rockwell Capital Partners, Inc. (“RPC”) and resulting issuance of shares of the Company to RCP under Section 34(a2)~~(10)~~ of the Securities Act of 1933, as amended (~~“Section~~the ~~3(a)(10)~~“Act”). ~~The~~since ~~Settlement~~the ~~Agreement~~foregoing ~~calls~~issuance ~~for~~did ~~the~~not ~~issuance~~involve ofa ~~shares~~public ofoffering, ~~Company~~the ~~common~~recipient ~~stock~~took ~~upon~~the ~~conversion~~securities offor ainvestment ~~promissory~~and ~~note~~not ~~issued~~resale, by the ~~Company~~recipient totook ~~RPC~~securities in ~~the~~exchange ~~principal~~for ~~amount~~other ofsecurities ~~$98,670.83~~already ~~issued~~held onin orthe ~~about September 14~~Company, ~~2016~~we ~~(the~~took ~~“Note”).~~appropriate ~~The~~measures ~~Agreement~~to ~~calls~~restrict ~~for~~transfer, ~~conversion~~and of the ~~principal~~recipient ~~amount~~had ofaccess ~~the~~to ~~Note~~similar todocumentation beand ~~converted~~information as ~~specified~~would be required in ~~the~~a ~~Agreement~~Registration ~~into~~Statement ~~Company~~under ~~common~~the ~~stock~~Act. ~~All~~ ~~shares~~No ofunderwriters ~~Company~~or ~~common~~agents ~~stock~~were ~~issued~~involved ~~thereunder~~in ~~shall~~the beforegoing ~~issued~~issuance ~~without~~and ~~restrictive~~the ~~legend~~Company ~~under~~paid ~~Section~~no ~~3(a)(10)~~underwriting discounts or commissions.

Item 95.0103 ~~Exhibits~~– AMENDMENT TO ARTICLES OF INCORPORATION OR BYLAWS

~~Exhibit~~On 99October 29, 2016, the Company filed a Certificate of Amendment with the Florida Secretary of State to increase its authorized capital of its common stock to One Hundred Billion (100,000,000,000) shares of Common Stock, par value $0.1001 ~~Settlement~~per ~~Agreement~~share. The Increase in Authorized was effective with the Florida Secretary of State on October 29, 2016, when the Certificate of Amendment was filed. The Increase in Authorized was approved by the Board of Directors and the shareholders holding a majority of the total issued and outstanding shares of common stock on October 28, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Rejuvel Bio-Sciences, Inc. Date: November 10, 2016 By: /s/ Charles J. Scimeca Charles J. Scimeca President and CEO

Date: October 27, 2016

By: /s/ Charles J. Scimeca

Charles J. Scimeca

President and CEO

Filing Compare · REJUVEL BIO-SCIENCES, INC.